Halia Therapeutics
A clinical-stage biopharmaceutical company advancing medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration.
Founded in 2017, the US company is advancing medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
The company's lead programs target NEK7 and LRRK2 inhibitors.
Latest Halia Therapeutics News & Features
17 November 2023
20 January 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze